UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 26, 2017
PROTAGONIST THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 001-37852 | | 98-0505495 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark, California 94560-1160
(Address of principal executive offices, including zip code)
(510) 474-0170
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Explanatory Note
On May 30, 2017, Protagonist Therapeutics, Inc. (“Protagonist” or “the Company”) filed a Current Report on Form 8-K (the “Original Report”) to report, among other things, that the Company entered into an exclusive license and collaboration agreement (the “Collaboration Agreement”) with Janssen Biotech, Inc. This Current Report on Form 8-K/A amends the Original Report solely to file the Collaboration Agreement as an exhibit hereto. The other disclosures made in the Original Report remain unchanged.
Item 9.01 Financial Statement and Exhibit
(d) Exhibits
Exhibit | | Description |
| | |
10.1† | | Exclusive License and Collaboration Agreement, by and between the Company and Janssen Biotech, Inc., dated May 26, 2017. |
† Confidential portions of this exhibit have been redacted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | Protagonist Therapeutics, Inc. |
| | | |
Dated: July 31, 2017 | | | |
| | | |
| | By: | /s/ Thomas P. O’Neil |
| | | Thomas P. O’Neil |
| | | Chief Financial Officer |
3
INDEX TO EXHIBITS
Exhibit | | Description | |
| | | |
10.1† | | Exclusive License and Collaboration Agreement, by and between the Company and Janssen Biotech, Inc., dated May 26, 2017. | |
† Confidential portions of this exhibit have been redacted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
4
